Table 1.
Characteristics | 25 ug n (%) | 30 ug n (%) |
---|---|---|
Number of injections | 110 | 364 |
Number of eyes a | 49 | 106 |
Eye | ||
OD | 54 (49.1) | 168 (46.2) |
OS | 56 (50.9) | 196 (53.8) |
Age at injection (years) | ||
Median (range) | 3 (1, 16) | 3 (0, 18) |
Weight (kg) at baseline | ||
Median (range) | 15 (5, 62) | 14 (7, 63) |
Reese-Ellsworth Stage | ||
Unknown | 0 | 231 |
2A | 2 (1.8) | 2 (1.5) |
2B | 2 (1.8) | 1 (0.8) |
3A | 3 (2.7) | 13 (9.8) |
3B | 7 (6.4) | 5 (3.8) |
4A | 6 (5.5) | 8 (6.0) |
4B | 5 (4.5) | 2 (1.5) |
5A | 20 (18.2) | 7 (5.3) |
5B | 65 (59.1) | 95 (71.4) |
International Classification of Retinoblastoma (ICRB) | ||
Unknown | 0 | 231 |
1 | 0 (0.0) | 1 (0.8) |
2 | 1 (0.9) | 7 (5.3) |
3 | 17 (15.5) | 4 (3.0) |
4 | 74 (67.3) | 99 (74.4) |
5 | 18 (16.4) | 22 (16.5) |
Time between injections | ||
Unknown | 0 | 6 |
No prior injections | 0 (0.0) | 1 (0.4) |
<=1 week | 0 (0.0) | 114 (44.4) |
1–2 weeks | 0 (0.0) | 19 (7.4) |
2–4 weeks | 36 (45.6) | 37 (14.4) |
4+ weeks | 43 (54.4) | 86 (33.5) |
Iris color | ||
Blue | 16 (14.5) | 65 (17.9) |
Light brown | 5 (4.5) | 96 (26.4) |
Dark brown | 89 (80.9) | 203 (55.8) |
Seed type | ||
Non-vitreous | 56 (50.9) | 90 (24.7) |
Vitreous | 54 (49.1) | 274 (75.3) |
Formulation | ||
No alcohol | 110 (100.0) | 109 (29.9) |
With alcohol | 0 (0.0) | 255 (70.1) |
Concomitant OAC | ||
No | 99 (90.0) | 294 (80.8) |
Yes | 11 (10.0) | 70 (19.2) |
Concomitant Topotecan | ||
No | 105 (95.5) | 312 (85.7) |
Yes | 5 (4.5) | 52 (14.3) |
Concomitant focal treatment | ||
No | 28 (25.5) | 234 (64.3) |
Yes | 82 (74.5) | 130 (35.7) |
New injection clock hour b | ||
Unknown | 8 | 19 |
No | 82 (80.4) | 250 (72.5) |
Yes | 20 (19.6) | 95 (27.5) |
The same eye could have received 25ug and 30ug injections. Therefore, the sum of the number of eyes from the two columns does not equal the number of eyes in the dataset.
New injection clock site hour was set to “No” for the 1st injection